Decoding Burkholderia: How Genomics Could Lead to New Weapons Against Deadly Infections
"Scientists are using functional and structural genomics to map the essential components of Burkholderia, paving the way for targeted drug development."
Burkholderia, a group of bacteria, poses a significant threat to human health, causing diseases like melioidosis, glanders, and severe pulmonary infections, especially in those with cancer or cystic fibrosis. What makes these infections particularly alarming is the increasing drug resistance, highlighting the urgent need for new and effective treatments. The race is on to find innovative ways to combat these resilient bacteria.
Traditional approaches to discovering new antimicrobials often involve structure-based drug design and phenotypic screens, both of which require a detailed understanding of the bacteria's essential proteins. High-resolution structures of these proteins are crucial for designing drugs that can precisely target and disrupt the bacteria's functions, ultimately leading to their demise.
Now, a team of scientists is pioneering a new approach: combining functional and structural genomics to map the essential components of Burkholderia. By identifying the genes critical for the bacteria's survival and determining the 3D structures of the corresponding proteins, they hope to create a powerful toolkit for developing the next generation of antibiotics. This article explores how this research is unlocking new possibilities for fighting these deadly infections.
Conventional Discovery Constraints
Established antimicrobial discovery approaches include structure-based drug design and whole-cell phenotypic screens followed by lead refinement. These methods often require high-resolution structures of proteins essential to the pathogen. Burkholderia infections are difficult to treat because the bacteria can have significant antibiotic resistance, including an outer-membrane penetration barrier and intrinsic polymyxin resistance linked to modified lipopolysaccharide.
Mapping Resistance Mechanisms
Research into Burkholderia resistance has examined integrons, quinolone resistance-determining region mutations, and efflux-pump activity. Earlier work identified the outer-membrane penetration barrier and modified lipopolysaccharide as important defenses against antimicrobials, including a basis for intrinsic polymyxin resistance. More recent research describes the Burkholderia cepacia complex as a 20-species group of non-fermenting gram-negative bacteria with intrinsic resistance and major hospital-associated importance.
Unlocking Burkholderia's Secrets: A Combined Genomics Approach
The research team started by experimentally identifying 406 genes in B. thailandensis--a less harmful relative of more dangerous Burkholderia species--that are likely essential for survival. This involved a technique called saturation-level transposon mutagenesis and next-generation sequencing (Tn-seq). In simple terms, they disrupted genes at random and then identified which disruptions were lethal to the bacteria. Those lethal genes are key.
- Ortholog Rescue: They looked for similar genes (orthologs) in other Burkholderia species. The idea is that slight variations in these related proteins might make them easier to study, while still providing useful structural information for drug design.
- Structural Coverage: This approach allowed them to obtain structures for 31 proteins from B. thailandensis and 25 orthologs from other species, covering 49 of the 406 essential gene families. In total, 88 structures were deposited into the Protein Data Bank, a public repository for structural data.
- Drug Target Analysis: The team then analyzed these protein structures for characteristics that would make them good drug targets, such as having no close human counterpart, being part of an essential metabolic pathway, and possessing a deep binding pocket where a drug molecule could attach. They identified 25 proteins meeting all these criteria.
From Structures to Essential Genes
Structural genomics has connected Burkholderia proteins with potential antimicrobial research targets. The hypothetical agmatinase from Burkholderia thailandensis, identified as PDB 4DZ4 through a structural genomics pipeline, showed the highest structural similarity to the E. coli agmatinase SPEB in the cited comparison. Separately, genome-wide TraDIS work identified the arn gene cluster BTH_I2189-BTH_I2195 in B. thailandensis as predicted essential by Tn-seq.
Targets Still Require Validation
Structural genomics can nominate proteins as possible drug targets, but structural evidence alone does not establish that inhibiting a target will treat infection. One study solved structures for 25 Burkholderia proteins considered worthy of further validation. The researchers specifically identified chemical validation as necessary to determine whether blocking a target affects cell growth and viability in vivo.
Variation in Essentiality and Treatment
The number of essential genes reported for infectious bacteria varies widely, from fewer than 200 to more than 600. Computational estimates for Burkholderia range from 312 to 649, showing that predictions can differ substantially from one another. This uncertainty matters clinically because Burkholderia cepacia complex infections, particularly in patients with cystic fibrosis, have limited therapeutic options due to intrinsic or acquired resistance, while antimicrobial-peptide and polymyxin resistance further complicate comparisons with other resistant gram-negative bacteria.
Why This Research Matters: A New Era in Antibiotic Discovery?
This research marks a significant step forward in the fight against Burkholderia infections. By combining functional genomics to identify essential genes with structural genomics to visualize the corresponding proteins, scientists have created a powerful platform for drug discovery. The "ortholog rescue" strategy offers a clever workaround to the challenges of protein structure determination, maximizing the potential for finding new drug targets.
Clinical Burden and Difficult Decisions
Clinically significant Burkholderia species create substantial diagnostic and therapeutic challenges because of their virulence and intrinsic antimicrobial resistance. Case-based research describes multidrug-resistant infection as a real clinical challenge in which resistance mechanisms can affect therapeutic strategy and outcome. The American Pharmaceutical Review also reports that B. cepacia complex can survive or multiply in some non-sterile, water-based products because of resistance to certain preservatives and antimicrobial agents, while detection requires validated methods.
The identification of 25 proteins with desirable drug target characteristics is particularly promising. These proteins represent potential Achilles' heels in Burkholderia, offering opportunities to develop highly targeted antibiotics with reduced risk of side effects. The availability of detailed structural information will accelerate the drug design process, allowing researchers to create molecules that precisely fit into the protein's binding pockets and disrupt its function.
While further research is needed to validate these targets and develop effective drugs, this study provides a valuable foundation for future efforts. As antibiotic resistance continues to rise, innovative approaches like this are essential for staying ahead of deadly bacterial infections and protecting public health.